# A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)

> **NCT00745823** · PHASE3 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 775 (actual)

## Conditions studied

- HIV

## Interventions

- **DRUG:** Comparator: Raltegravir 400 mg b.i.d.
- **DRUG:** Experimental: Raltegravir 800 mg q.d.
- **DRUG:** TRUVADA™

## Key facts

- **NCT ID:** NCT00745823
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-09
- **Primary completion:** 2010-10
- **Final completion:** 2011-05
- **Target enrollment:** 775 (ACTUAL)
- **Why stopped:** Primary efficacy analysis at Week 48 did not demonstrate non-inferiority of raltegravir 800 mg once daily versus raltegravir 400 mg twice daily
- **Last updated:** 2017-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00745823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00745823, "A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00745823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*